Patents by Inventor Walter Szarek
Walter Szarek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7244764Abstract: Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-+related disease.Type: GrantFiled: June 18, 2004Date of Patent: July 17, 2007Assignee: Neurochem (International) LimitedInventors: Xianqi Kong, Walter A. Szarek, Francine Gervais
-
Publication number: 20070015737Abstract: Methods and compositions which are useful in the treatment of amyloidosis. In particular, methods and compositions are provided for inhibiting, preventing and treating amyloid depositions, e.g. in pancreatic islets, wherein the amyloidotic deposits are islet amyloid polypeptide (IAPP)-associated amyloid deposition or deposits. The methods of the invention involved administering to a subject a therapeutic compound which inhibits IAPP-associated amyloid deposits. Accordingly, the compositions and method of the invention are useful for inhibiting IAPP-associated amyloidosis in disorders in which such amyloid deposition occurs, such an diabetes. The invention also provides a process for the preparation of cells suitable for transplantation into a mammal, which cells are capable of forming fibrils, said process comprising contacting the cells with an inhibitor of fibril formation. In particular the process prepares cells for use in a method of treating diabetes.Type: ApplicationFiled: November 2, 2005Publication date: January 18, 2007Applicants: Neurochem (International) Limited, Isis Innovation Limited, Queen's University at Kingston, The University of British ColumbiaInventors: Anne Clark, Paul Fraser, Bruce Verchere, Ajay Gupta, David Migneault, Walter Szarek
-
Publication number: 20070004680Abstract: The present invention relates to compositions and methods to modulate the activity of gated ion channels.Type: ApplicationFiled: March 30, 2005Publication date: January 4, 2007Applicant: PainCeptor Pharma CorporationInventors: Kazimierz Babinski, Walter Szarek, Rahul Vohra, Thomas Varming, Philip Ahring, Tino Joergensen, Gordon Blackburn-Munro
-
Publication number: 20060167095Abstract: Therapeutic compounds and methods for inhibiting amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is inhibited by the administration to a subject of an effective amount of a therapeutic compound comprising an anionic group and a carrier molecule, or a pharmaceutically acceptable salt thereof, such that an interaction between an amyloidogenic protein and a basement membrane constituent is inhibited. Preferred anionic groups are sulfonates and sulfates. Preferred carrier molecules include carbohydrates, polymers, peptides, peptide derivatives, aliphatic groups, alicyclic groups, heterocyclic groups, aromatic groups and combinations thereof.Type: ApplicationFiled: December 22, 2005Publication date: July 27, 2006Inventors: Robert Kisilevsky, Walter Szarek, Donald Weaver
-
Publication number: 20060135479Abstract: Therapeutic compounds and methods for modulating amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is modulated by the administration to a subject of an effective amount of a therapeutic compound comprising a phosphonate group and a carboxylate group, a congener thereof, or a pharmaceutically acceptable salt or ester thereof. In preferred embodiments, an interaction between an amyloidogenic protein and a basement membrane constituent is modulated.Type: ApplicationFiled: October 7, 2005Publication date: June 22, 2006Inventors: Walter Szarek, Xianqi Kong, Gregory Thatcher, Boris Gorine
-
Publication number: 20050282840Abstract: Disclosed are compositions which modulate the interaction of nerve growth factor and brain-derived neurotrophic factor with neurotrophic receptors. Also disclosed are methods of using the compositions of the invention, including methods of administration.Type: ApplicationFiled: February 11, 2005Publication date: December 22, 2005Applicants: PainCeptor Pharma Corporation, Queen's University at KingstonInventors: Gregory Ross, Walter Szarek, Rahul Vohra
-
Publication number: 20050038117Abstract: Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid- +related disease.Type: ApplicationFiled: June 18, 2004Publication date: February 17, 2005Applicants: Neurochem (International) Limited, Queen's University at Kingston, Neurochem, Inc.Inventors: Xianqi Kong, Walter Szarek, Francine Gervais
-
Publication number: 20040248876Abstract: Methods and compositions which are useful in the treatment of amyloidosis. In particular, methods and compositions are provided for inhibiting, preventing and treating amyloid deposition, e.g., in pancreatic islets, wherein the amyloidotic deposits are islet amyloid polypeptide (IAPP)-associated amyloid deposition or deposits. The methods of the invention involve administering to a subject a therapeutic compound which inhibits IAPP-associated amyloid deposits. Accordingly, the compositions and methods of the invention are useful for inhibiting IAPP-associated amyloidosis in disorders in which such amyloid deposition occurs, such as diabetes.Type: ApplicationFiled: May 2, 2003Publication date: December 9, 2004Applicant: Queen's University at Kingston and Neurochem, Inc.Inventors: Walter A. Szarek, Donald F. Weaver, Xianqi Kong, Ajay Gupta, David Migneault
-
Publication number: 20040208875Abstract: Therapeutic compounds and methods for inhibiting amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is inhibited by the administration to a subject of an effective amount of a therapeutic compound comprising an anionic group and a carrier molecule, or a pharmaceutically acceptable salt thereof, such that an interaction between an amyloidogenic protein and a basement membrane constituent is inhibited. Preferred anionic groups are sulfonates and sulfates. Preferred carrier molecules include carbohydrates, polymers, peptides, peptide derivatives, aliphatic groups, alicyclic groups, heterocyclic groups, aromatic groups and combinations thereof.Type: ApplicationFiled: February 11, 2004Publication date: October 21, 2004Applicant: Queen's University at KingstonInventors: Robert Kisilevsky, Walter Szarek, Donald Weaver
-
Publication number: 20040198832Abstract: Therapeutic compounds and methods for modulating amyloid aggregation in a subject, whatever its clinical setting, are described.Type: ApplicationFiled: August 11, 2003Publication date: October 7, 2004Applicants: Queen's University at Kingston, Neurochem (International) LimitedInventors: Walter A. Szarek, Donald F. Weaver, Xianqi Kong, Heather Gordon
-
Publication number: 20040138178Abstract: Therapeutic compounds and methods for modulating amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is modulated by the administration to a subject of an effective amount of a therapeutic compound comprising a phosphonate group and a carboxylate group, a congener thereof, or a pharmaceutically acceptable salt or ester thereof. In preferred embodiments, an interaction between an amyloidogenic protein and a basement membrane constituent is modulated.Type: ApplicationFiled: May 27, 2003Publication date: July 15, 2004Applicant: Queen's University at KingstonInventors: Walter A. Szarek, Xianqi Kong, Gregory R.J. Thatcher, Boris Gorine
-
Publication number: 20030108595Abstract: Therapeutic compounds and methods for inhibiting amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is inhibited by the administration to a subject of an effective amount of a therapeutic compound comprising an anionic group and a carrier molecule, or a pharmaceutically acceptable salt thereof, such that an interaction between an amyloidogenic protein and a basement membrane constituent is inhibited. Preferred anionic groups are sulfonates and sulfates. Preferred carrier molecules include carbohydrates, polymers, peptides, peptide derivatives, aliphatic groups, alicyclic groups, heterocyclic groups, aromatic groups and combinations thereof.Type: ApplicationFiled: April 18, 2002Publication date: June 12, 2003Applicant: Queen's University at KingstonInventors: Robert Kisilevsky, Walter Szarek, Donald Weaver
-
Patent number: 6562836Abstract: Methods and compositions which are useful in the treatment of amyloidosis. In particular, methods and compositions are provided for inhibiting, preventing and treating amyloid deposition, e.g., in pancreatic islets, wherein the amyloidotic deposits are islet amyloid polypeptide (IAPP)-associated amyloid deposition or deposits. The methods of the invention involve administering to a subject a therapeutic compound which inhibits IAPP-associated amyloid deposits. Accordingly, the compositions and methods of the invention are useful for inhibiting IAPP-associated amyloidosis in disorders in which such amyloid deposition occurs, such as diabetes.Type: GrantFiled: May 23, 2000Date of Patent: May 13, 2003Assignee: Queen's University of KingstonInventors: Walter A. Szarek, Donald F. Weaver, Xianqi Kong, Ajay Gupta, David Migneault
-
Publication number: 20030027796Abstract: Therapeutic compounds and methods for modulating amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is modulated by the administration to a subject of an effective amount of a therapeutic compound comprising a phosphonate group and a carboxylate group, a congener thereof, or a pharmaceutically acceptable salt or ester thereof. In preferred embodiments, an interaction between an amyloidogenic protein and a basement membrane constituent is modulated.Type: ApplicationFiled: August 23, 2002Publication date: February 6, 2003Applicant: Lahive & Cockfield, LLPInventors: Walter A. Szarek, Xianqi Kong, Gregory R.J. Thatcher, Boris Gorine
-
Patent number: 6440952Abstract: Therapeutic compounds and methods for modulating amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is modulated by the administration to a subject of an effective amount of a therapeutic compound comprising a phosphonate group and a carboxylate group, a congener thereof, or a pharmaceutically acceptable salt or ester thereof. In preferred embodiments, an interaction between an amyloidogenic protein and a basement membrane constituent is modulated.Type: GrantFiled: May 17, 2001Date of Patent: August 27, 2002Assignee: Queen's University at KingstonInventors: Walter A. Szarek, Xianqi Kong, Gregory R. J. Thatcher, Boris Gorine
-
Patent number: 6329356Abstract: Therapeutic compounds and methods for modulating amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is modulated by the administration to a subject of an effective amount of a therapeutic compound comprising a phosphonate group and a carboxylate group, a congener thereof, or a pharmaceutically acceptable salt or ester thereof. In preferred embodiments, an interaction between an amyloidogenic protein and a basement membrane constituent is modulated.Type: GrantFiled: April 8, 1999Date of Patent: December 11, 2001Assignees: Neurochem, Inc., Queen's University At KingstonInventors: Walter A. Szarek, Xianqi Kong
-
Publication number: 20010048941Abstract: Therapeutic compounds and methods for inhibiting amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is inhibited by the administration to a subject of an effective amount of a therapeutic compound comprising an anionic group and a carrier molecule, or a pharmaceutically acceptable salt thereof, such that an interaction between an amnyloidogenic protein and a basement membrane constituent is inhibited. Preferred anionic groups are sulfonates and sulfates.Type: ApplicationFiled: February 9, 2001Publication date: December 6, 2001Applicant: Queen's University of KingstonInventors: Robert Kisilevsky, Walter Szarek, Donald Weaver
-
Publication number: 20010027186Abstract: Therapeutic compounds and methods for modulating amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is modulated by the administration to a subject of an effective amount of a therapeutic compound comprising a phosphonate group and a carboxylate group, a congener thereof, or a pharmaceutically acceptable salt or ester thereof. In preferred embodiments, an interaction between an amyloidogenic protein and a basement membrane constituent is modulated.Type: ApplicationFiled: May 17, 2001Publication date: October 4, 2001Applicant: Queen's University at KingstonInventors: Walter A. Szarek, Xianqi Kong, Gregory R.J Thatcher, Boris Gorine
-
Patent number: 5972328Abstract: Therapeutic compounds and methods for inhibiting amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is inhibited by the administration to a subject of an effective amount of a therapeutic compound comprising an anionic group and a carrier molecule, or a pharmaceutically acceptable salt thereof, such that an interaction between an amyloidogenic protein and a basement membrane constituent is inhibited. Preferred anionic groups are sulfonates and sulfates. Preferred carrier molecules include carbohydrates, polymers, peptides, peptide derivatives, aliphatic groups, alicyclic groups, heterocyclic groups, aromatic groups and combinations thereof.Type: GrantFiled: June 5, 1995Date of Patent: October 26, 1999Assignee: Queen's University at KingstonInventors: Robert Kisilevsky, Walter Szarek, Donald Weaver
-
Patent number: 5869469Abstract: Therapeutic compounds and methods for modulating amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is modulated by the administration to a subject of an effective amount of a therapeutic compound comprising a phosphonate group and a carboxylate group, or a pharmaceutically acceptable salt or ester thereof. In preferred embodiments, an interaction between an amyloidogenic protein and a basement membrane constituent is modulated.Type: GrantFiled: August 18, 1997Date of Patent: February 9, 1999Assignee: Queen's University at KingstonInventors: Walter A. Szarek, Xianqi Kong